Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

about

A practical review on carfilzomib in multiple myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.

P2860

Q38740271-088DC48F-E9ED-430B-AF86-B7DE48C3B758 Q39100317-CE8FF67B-8431-4447-8D4C-5C4B99E5569A

P2860

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

Item

http://www.wikidata.org/entity/Q41184318

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

@en

type

Item

label

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

@en

prefLabel

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

@en

P1476

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

@en

P2093

Abdel Rahman Lataifeh

http://www.w3.org/2001/XMLSchema#string

Ahmad Nusair

http://www.w3.org/2001/XMLSchema#string

P2860

A method for estimating the probability of adverse drug reactions

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.

P304

720-724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155215588630

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26044587

http://www.w3.org/2001/XMLSchema#string

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

about

P2860

P2860

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698